The field of nucleic acid chemistry has witnessed remarkable advancements in recent years, revolutionizing our understanding of synthesis, functionality and therapeutic applications. This webinar will explore the cutting-edge developments that are shaping the future of this dynamic discipline.
The expert speakers will begin by delving into the latest breakthroughs in nucleic acid synthesis, including novel methodologies for the efficient and precise construction of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) molecules. These innovations not only enhance our ability to manipulate genetic material but also pave the way for the creation of synthetic nucleic acids with tailored properties.
Next, they will examine the functional aspects of nucleic acids, focusing on their roles beyond traditional genetic encoding. From catalytic RNAs to nucleic acid-based nanostructures, they will highlight how these molecules are being engineered to perform diverse biological and chemical functions, opening new avenues for research and application.
Finally, the presentation will address the transformative impact of nucleic acid chemistry on therapeutic development. They will discuss the emergence of nucleic acid-based drugs, such as mRNA vaccines, siRNA therapies and CRISPR-based gene editing tools, which are revolutionizing medicine by offering targeted and personalized treatment options.
By bridging the gaps between synthesis, function and therapeutic application, this presentation will underscore the pivotal role of nucleic acid chemistry in driving innovation across multiple scientific and medical domains.
Join this webinar to explore the frontiers of nucleic acid chemistry and its potential to shape the future of biotechnology and healthcare.
Speakers
Dr. Jinsen Chen, Executive Director of Nucleic Acid Chemistry, HitGen Inc.
Dr. Jinsen Chen is a seasoned expert in nucleic acid chemistry and Contract Research, Development, and Manufacturing Organization (CRDMO) services. He holds a PhD in Chemistry from Nanjing University and completed postdoctoral research at the University of Colorado Boulder and Michigan Technological University (USA). Currently, he serves as the General Manager of Hitston Ltd. (a joint venture between HitGen and Easton) and Executive Director of Nucleic Acid Chemistry at HitGen.
With over a decade of experience in nucleic acid technology R&D and industrialization, Dr. Chen specializes in end-to-end solutions spanning modified nucleoside synthesis → oligonucleotide solid-phase synthesis → bioconjugation → CRDMO delivery. He also serves as a committee member of the Nucleic Acid Drug Division at the Chinese Pharmaceutical Association.
Message Presenter
Dr. Minghong Zhong, CEO, GeneLancet Biosciences Inc.
Dr. Minghong Zhong has worked in the drug discovery industry for over 25 years. He is the inventor of multiple patents. Dr. Zhong is the scientific founder and CEO of GeneLancet, a gene editing company developing precise next-generation gene editing. Prior to GeneLancet, he was a Principal Scientist at Janssen Pharmaceuticals (Johnson & Johnson).
His expertise includes both medicinal chemistry and nucleic acid therapeutics. Dr. Zhong holds an adjunct professor (Translational Medicine) position at Baruch S. Blumberg Institute. He received his doctoral degree from Brigham Young University and completed his postdoctoral research at Yale University.
Message PresenterWho Should Attend?
This webinar will appeal to professionals with the following job titles or those working in the following fields:
- Biotechnology/Molecular Biology/DNA Sequencing
- Senior Vice President/Vice President, Research
- Senior Research Director/Research Director
- Chief Executive Officer/Chief Scientific Officer
- Lead Researcher/Head of Research
- Pharmaceuticals
- Medical research institutions
- Universities specializing in biomedicine
What You Will Learn
Attendees will learn about:
- Novel methodologies for precise and efficient DNA and RNA synthesis
- Exploration of nucleic acids beyond genetic encoding, including catalytic RNAs and nucleic acid-based nanostructures
- The role of nucleic acid-based drugs in modern medicine, including mRNA vaccines and siRNA therapies
- How advancements in nucleic acid chemistry connect different scientific and medical domains
Xtalks Partner
HitGen Inc
HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK, and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account